Chiltern Wins CRO Leadership Award From Life Science Leader

LONDON and WILMINGTON, North Carolina, March 6, 2014 /PRNewswire/ --Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Chiltern has been recognized with a CRO Leadership Award in all five categories: Quality, Reliability, Productivity, Innovation and Regulatory. The awards are given by Life Science Leader publication based on the data-driven research of Nice Insight. Chiltern is the only organization to be recognized in all five categories for three straight years.

The CRO Leadership Awards were developed to better serve pharmaceutical and biopharmaceutical executives in their vetting process of CROs when they have a new project. On an annual basis, Nice Insight conducts a pharmaceutical and biotechnology survey deployed to over 40,000 outsourcing-facing biotech and pharma executives. Companies achieving top 20 percentile perception scores in the areas of Innovation, Productivity, Quality, Regulatory, and Reliability will be recognized for their achievement.

"At Life Science Leader, we think having data-driven awards is more objective and valuable than having those awarded as a result of a nomination and voting process. The winners should be proud of these awards because they were determined by data gathered from customers," stated Rob Wright, Editor in Chief, Life Science Leader.

Jim Esinhart, Chiltern CEO, commented, "We are extremely proud to be recognized by the biopharmaceutical industry as a CRO leader in Quality, Reliability, Productivity, Innovation and Regulatory. Chiltern has won this award for three consecutive years and it is a testament to the commitments by our amazing staff to deliver Innovation, Quality and Flexibility for all our clients. It is with great pleasure that I accept this award on behalf of all Chiltern colleagues."

Company profile

About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.